Connor, Clark & Lunn Investment Management (CC&L)
MLYS icon

Connor, Clark & Lunn Investment Management (CC&L)’s Mineralys Therapeutics MLYS Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,860
Closed -$249K – 1694
2025
Q4 		$249K Sell
6,860
-7,389
-52% -$296K ﹤0.01% 1421
2025
Q3 		$540K Buy
+14,249
New +$308K ﹤0.01% 1238

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s MLYS Position: Q1 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Mineralys Therapeutics (MLYS) in Q1 2026, closing a stake of 6,860 shares — an estimated $249K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in MLYS in Q3 2025 and held it in 2 quarters. The position peaked at $540K in Q3 2025. 215 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Mineralys Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 6,860 Mineralys Therapeutics shares in Q1 2026, an estimated $249K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Mineralys Therapeutics in Q3 2025 and held it in 2 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Mineralys Therapeutics position peaked at $540K in Q3 2025.
  • 215 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2026, filed 11 May 2026.